Accordingly, coupling FK866 therapy to our NAPRT inhibitors would presumably reverse the protective effect of the intestinal bacteria and restore the anti-tumor effect of NAMPT inhibitors in vivo. The gene discussed is NAMPT; the disease is neoplasm.